This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
by Zacks Equity Research
Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.
HYPR Stock Jumps on NVIDIA Partnership to Advance AI Neuroimaging
by Zacks Equity Research
Hyperfine partners with NVIDIA to integrate advanced AI into its Swoop MRI system, aiming to transform neuroimaging with faster and more accessible brain scan solutions.
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
by Zacks Equity Research
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Should You Retain IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton
by Zacks Equity Research
LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
by Zacks Equity Research
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
Compelling Weight Management Program Data Set to Boost CVS Stock
by Zacks Equity Research
CVS Health shares impressive findings from its Weight Management Program.
BioSpin's Innovations to Support Bruker Shares, Macro Issues to Ail
by Zacks Equity Research
BRKR NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
by Zacks Equity Research
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Stryker Unveils Next-Generation Mako SmartRobotics but Stock Falls
by Zacks Equity Research
SYK unveils next-gen Mako SmartRobotics, revolutionizing hip, knee and spine surgeries with greater precision and first-to-market robotic hip revision technology.
RMD Stock Likely to Benefit From the New Brand Evolution Strategy
by Zacks Equity Research
In another major brand update, Resmed is likely to unify all the brands under one identity.
Here's Why You Should Add Veeva Systems Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
TECH Stock Might Rise Following the Leo Shipping Announcement
by Zacks Equity Research
Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
by Zacks Equity Research
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
GEHC Stock May Gain as Genesis Portfolio Expands Cloud Offerings
by Zacks Equity Research
GE HealthCare unveils Genesis, a cloud-based imaging portfolio designed to enhance healthcare efficiency, streamline data access, and drive digital transformation.
Here's Why You Should Retain HealthEquity Stock in Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
EPD Expansion Supports Abbot Stock, Macro Issues Prevail
by Zacks Equity Research
ABT's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
ALGN Stock to Benefit From the Launch of Align X-ray Insights Solution
by Zacks Equity Research
Align Technologies unveils Align X-ray Insights, an AI-backed CADe solution.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Boston Scientific Gains 42.2% in a Year: What's Driving the Stock?
by Zacks Equity Research
BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Indrajit Bandyopadhyay
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.